IL254639B - Digital analysis of cancer cells moving in the bloodstream in blood samples - Google Patents

Digital analysis of cancer cells moving in the bloodstream in blood samples

Info

Publication number
IL254639B
IL254639B IL254639A IL25463917A IL254639B IL 254639 B IL254639 B IL 254639B IL 254639 A IL254639 A IL 254639A IL 25463917 A IL25463917 A IL 25463917A IL 254639 B IL254639 B IL 254639B
Authority
IL
Israel
Prior art keywords
tumor cells
blood samples
circulating tumor
digital analysis
analysis
Prior art date
Application number
IL254639A
Other languages
English (en)
Hebrew (he)
Other versions
IL254639A0 (en
Original Assignee
Massachusetts Gen Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Gen Hospital filed Critical Massachusetts Gen Hospital
Publication of IL254639A0 publication Critical patent/IL254639A0/en
Publication of IL254639B publication Critical patent/IL254639B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6816Hybridisation assays characterised by the detection means
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6851Quantitative amplification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/686Polymerase chain reaction [PCR]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/107Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/159Microreactors, e.g. emulsion PCR or sequencing, droplet PCR, microcapsules, i.e. non-liquid containers with a range of different permeability's for different reaction components
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00Nucleic acid analysis characterised by mode or means of detection
    • C12Q2565/60Detection means characterised by use of a special device
    • C12Q2565/629Detection means characterised by use of a special device being a microfluidic device
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/16Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL254639A 2015-03-25 2017-09-24 Digital analysis of cancer cells moving in the bloodstream in blood samples IL254639B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562137891P 2015-03-25 2015-03-25
US201562219339P 2015-09-16 2015-09-16
US201562253619P 2015-11-10 2015-11-10
PCT/US2016/024367 WO2016154600A1 (en) 2015-03-25 2016-03-25 Digital analysis of circulating tumor cells in blood samples

Publications (2)

Publication Number Publication Date
IL254639A0 IL254639A0 (en) 2017-11-30
IL254639B true IL254639B (en) 2021-10-31

Family

ID=56977798

Family Applications (1)

Application Number Title Priority Date Filing Date
IL254639A IL254639B (en) 2015-03-25 2017-09-24 Digital analysis of cancer cells moving in the bloodstream in blood samples

Country Status (10)

Country Link
US (3) US20180057889A1 (cg-RX-API-DMAC7.html)
EP (1) EP3274476B1 (cg-RX-API-DMAC7.html)
JP (2) JP7144934B2 (cg-RX-API-DMAC7.html)
KR (1) KR102502087B1 (cg-RX-API-DMAC7.html)
CN (1) CN107614698A (cg-RX-API-DMAC7.html)
AU (2) AU2016238253B2 (cg-RX-API-DMAC7.html)
CA (1) CA2980562A1 (cg-RX-API-DMAC7.html)
ES (1) ES2954456T3 (cg-RX-API-DMAC7.html)
IL (1) IL254639B (cg-RX-API-DMAC7.html)
WO (1) WO2016154600A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107326085B (zh) 2012-02-03 2022-05-03 加州理工学院 多路生化测定中信号的编码和解码
CN107614698A (zh) 2015-03-25 2018-01-19 通用医疗公司 对血液样品中的循环肿瘤细胞的数字分析
US11371101B2 (en) 2016-10-27 2022-06-28 The General Hospital Corporation Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers
US20180252722A1 (en) * 2017-03-05 2018-09-06 Yan Wang PCR-based Method for Counting Circulating Tumor Cells
US11597963B2 (en) * 2017-11-09 2023-03-07 Biomillenia Sas Microbial selection system
WO2019165242A1 (en) * 2018-02-23 2019-08-29 Paraskevi Giannakakou Assay for detection of androgen receptor variants
CN108535145A (zh) * 2018-03-09 2018-09-14 深圳市瑞图生物技术有限公司 快速检测外周血液中网织红细胞数量的方法及装置
CN112424377A (zh) 2018-04-17 2021-02-26 克罗玛科德公司 用于多重分析的方法和系统
CN110456034B (zh) * 2018-05-07 2022-07-22 上海市第十人民医院 一种循环肿瘤细胞的检测方法
US20210172950A1 (en) 2018-06-29 2021-06-10 The General Hospital Corporation Isolating and analyzing rare brain-derived cells and particles
US12203129B2 (en) * 2018-07-03 2025-01-21 ChromaCode, Inc. Formulations and signal encoding and decoding methods for massively multiplexed biochemical assays
WO2020055954A2 (en) * 2018-09-11 2020-03-19 The General Hospital Corporation Methods for detecting liver diseases
KR102380529B1 (ko) * 2020-04-29 2022-03-31 인제대학교 산학협력단 전이성 전립선 암의 진단 및 예후 예측을 위한 혈중종양세포 기반 바이오 마커 조성물
CN112662774A (zh) * 2021-01-12 2021-04-16 南方医科大学南方医院 一种肝癌循环肿瘤细胞标志物及其应用
CN114395622A (zh) * 2021-12-13 2022-04-26 深圳先进技术研究院 一种利用数字pcr检测循环肿瘤细胞egfr基因突变的方法及其应用
DE102022211089A1 (de) * 2022-10-19 2024-04-25 Robert Bosch Gesellschaft mit beschränkter Haftung Kombinierte Zellspezifische Markierung und Anreicherung von Biomarkern

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120252015A1 (en) * 2011-02-18 2012-10-04 Bio-Rad Laboratories Methods and compositions for detecting genetic material
WO2014028378A2 (en) * 2012-08-13 2014-02-20 The Regents Of The University Of California Methods and systems for detecting biological components

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US889A (en) 1838-08-20 Mode of constructing metal bench-vises
US8535A (en) 1851-11-18 Stove-geate
DE29623597U1 (de) 1996-11-08 1999-01-07 Eppendorf - Netheler - Hinz Gmbh, 22339 Hamburg Temperierblock mit Temperiereinrichtungen
US20080050393A1 (en) 1998-12-03 2008-02-28 Tang Y Tom Novel nucleic acids and polypeptides
CA2311201A1 (en) * 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins
WO2002012328A2 (en) * 2000-08-03 2002-02-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20030143539A1 (en) 2000-12-08 2003-07-31 Francois Bertucci Gene expression profiling of primary breast carcinomas using arrays of candidate genes
EP1399593A2 (en) 2001-05-16 2004-03-24 Novartis AG Genes expressed in breast cancer as prognostic and therapeutic targets
US20030073623A1 (en) 2001-07-30 2003-04-17 Drmanac Radoje T. Novel nucleic acid sequences obtained from various cDNA libraries
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20060275794A1 (en) 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
US20070026417A1 (en) * 2005-07-29 2007-02-01 Martin Fuchs Devices and methods for enrichment and alteration of circulating tumor cells and other particles
WO2006121991A2 (en) 2005-05-06 2006-11-16 Diadexus, Inc. Compositions and methods for detection, prognosis and treatment of breast cancer
CA2652052A1 (en) * 2006-05-16 2007-11-29 Nugen Technologies, Inc. Nucleic acid separation and purification method based on reversible charge interactions
EP2589668A1 (en) * 2006-06-14 2013-05-08 Verinata Health, Inc Rare cell analysis using sample splitting and DNA tags
WO2009051734A1 (en) * 2007-10-17 2009-04-23 The General Hospital Corporation Microchip-based devices for capturing circulating tumor cells and methods of their use
US9068181B2 (en) 2008-05-23 2015-06-30 The General Hospital Corporation Microfluidic droplet encapsulation
US9625454B2 (en) * 2009-09-04 2017-04-18 The Research Foundation For The State University Of New York Rapid and continuous analyte processing in droplet microfluidic devices
US20110166030A1 (en) * 2009-09-30 2011-07-07 Yixin Wang Prediction of response to docetaxel therapy based on the presence of TMPRSSG2:ERG fusion in circulating tumor cells
CA2789425C (en) 2010-02-12 2020-04-28 Raindance Technologies, Inc. Digital analyte analysis with polymerase error correction
WO2011112903A2 (en) * 2010-03-11 2011-09-15 Board Of Regents, The University Of Texas System Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of breast cancer patients
AU2015268617A1 (en) 2010-03-31 2016-01-07 Sividon Diagnostics Gmbh Method for breast cancer recurrence prediction under endocrine treatment
CA2793133C (en) 2010-03-31 2019-08-20 Sividon Diagnostics Gmbh Method for breast cancer recurrence prediction under endocrine treatment
US9650629B2 (en) * 2010-07-07 2017-05-16 Roche Molecular Systems, Inc. Clonal pre-amplification in emulsion
AU2011291599B2 (en) 2010-08-18 2015-09-10 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for disease
WO2012115885A1 (en) 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
WO2012135397A2 (en) 2011-03-29 2012-10-04 Lisanti Michael P Lactate-and ketones-induced gene signatures and use the same for diagnosing disease and predicting clinical outcome
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
EP2771685B1 (en) * 2011-10-24 2018-06-13 The General Hospital Corporation Biomarkers of cancer
WO2014008155A1 (en) 2012-07-02 2014-01-09 The General Hospital Corporation Diagnosis and monitoring treatment of prostate cancer
AU2013315128B2 (en) 2012-09-14 2019-01-03 Memorial Sloan-Kettering Cancer Center Genes associated with dasatinib sensitivity
WO2014047285A1 (en) 2012-09-19 2014-03-27 Paraskevi Giannakakou Identifying taxane sensitivity in prostate cancer patients
WO2014075067A1 (en) 2012-11-12 2014-05-15 Nanostring Technologies, Inc. Methods to predict breast cancer outcome
WO2014165762A1 (en) 2013-04-05 2014-10-09 Raindance Technologies, Inc. Rare cell analysis after negative selection
CA2920317A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
EP3560591B1 (en) 2013-10-18 2021-02-17 The General Hospital Corporation Microfluidic sorting using high gradient magnetic fields
AU2015228860A1 (en) 2014-03-13 2016-09-08 F. Hoffmann-La Roche Ag Methods and compositions for modulating estrogen receptor mutants
BR112016024332A2 (pt) 2014-05-21 2017-08-15 Hoffmann La Roche métodos para o tratamento, para a determinação dos compostos a serem utilizados, para a seleção de pacientes, para a monitoração da eficácia terapêutica, para a optimização da eficácia terapêutica, para a identificação de um biomarcador, artigo de fabricação, utilização de gdc-0941, gdc-0941 e um agente de terapia endócrina e composto para a utilização
WO2016094904A1 (en) 2014-12-12 2016-06-16 Celcuity Llc Methods of measuring erbb signaling pathway activity to diagnose and treat cancer patients
US20180057899A1 (en) 2015-02-20 2018-03-01 Comelz S.P.A. Method for cutting natural hides and the like
LT3268493T (lt) 2015-03-12 2022-03-10 Janssen Pharmaceutica Nv Viso kraujo mrnr žymenys, skirti prostatos vėžio prognozavimui, ir jo nustatymo būdai
CN107614698A (zh) 2015-03-25 2018-01-19 通用医疗公司 对血液样品中的循环肿瘤细胞的数字分析
US11371101B2 (en) 2016-10-27 2022-06-28 The General Hospital Corporation Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120252015A1 (en) * 2011-02-18 2012-10-04 Bio-Rad Laboratories Methods and compositions for detecting genetic material
WO2014028378A2 (en) * 2012-08-13 2014-02-20 The Regents Of The University Of California Methods and systems for detecting biological components

Also Published As

Publication number Publication date
JP7203128B2 (ja) 2023-01-12
US20180057889A1 (en) 2018-03-01
AU2016238253A1 (en) 2017-10-19
AU2022231734A1 (en) 2022-11-10
US20240132969A1 (en) 2024-04-25
EP3274476A1 (en) 2018-01-31
WO2016154600A1 (en) 2016-09-29
KR20170131516A (ko) 2017-11-29
US20210189501A1 (en) 2021-06-24
JP2021087428A (ja) 2021-06-10
CN107614698A (zh) 2018-01-19
IL254639A0 (en) 2017-11-30
KR102502087B1 (ko) 2023-02-20
US11898209B2 (en) 2024-02-13
EP3274476B1 (en) 2023-06-07
AU2016238253B2 (en) 2022-06-16
JP2018513679A (ja) 2018-05-31
EP3274476A4 (en) 2018-08-29
HK1249553A1 (en) 2018-11-02
CA2980562A1 (en) 2016-09-29
ES2954456T3 (es) 2023-11-22
JP7144934B2 (ja) 2022-09-30

Similar Documents

Publication Publication Date Title
IL254639B (en) Digital analysis of cancer cells moving in the bloodstream in blood samples
DK3899030T3 (en) Methods for analysis of circulating cells
GB2556436B (en) Cell population analysis
IL254734B1 (en) Modified t cells and methods of making and using the same
IL253795B (en) Methods for treating cancer using activated t cells
IL257052A (en) Enhancing blood cell estimation
EP4112738C0 (en) MULTIGENE ANALYSIS OF TUMOR SAMPLES
AP2016009549A0 (en) Methods for increasing red blood cell levels and treating sickle-cell disease
EP2967509A4 (en) COLLECTION AND CONSERVATION OF BIOLOGICAL SAMPLES
EP3186397A4 (en) Use of circulating cell biomarkers in the blood for detection and diagnosis of diseases and methods of isolating them
IL267315A (en) Methods of determining colorectal cancer status in an individual
SG11201507949YA (en) Biological sample processing
EP3129472A4 (en) Microtentacle imaging in patient tumor samples
IL257049A (en) Compositions and methods for measuring blood glucose levels
SG11201702377QA (en) Blood sample management using open cell foam
SG11201606297UA (en) Blood sample management using open cell foam
EP3054001A4 (en) Device for concentration and separation of circulating tumor cells, and method for concentration and separation of circulating tumor cells
IL245766A0 (en) Different levels in blood cell samples of emt markers for the diagnosis of cancer, in particular colon cancer (crc) and pancreatic cancer (pc)
SG11201700876RA (en) Methods and compositions for analyzing glucose-6-phosphate dehydrogenase activity in blood samples
EP3108246A4 (en) Methods for analyzing rare circulating cells
DK3271864T3 (da) Vævsprøveanalyseteknik
GB201502579D0 (en) Cell analysis using dynamic biophysical methods
SG11201506406XA (en) Method for detecting shed or circulating tumor cells in biological fluids
PT3298165T (pt) Método e kit para diagnóstico de cancro colorretal
EP3405095C0 (en) TISSUE SAMPLE ANALYSIS